OOIR: Observatory of International Research

Papers

(The H4-Index of International Journal of Antimicrobial Agents is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Increased antimicrobial resistance during the COVID-19 pandemic	279
Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update	183
Different mutations in SARS-CoV-2 associate with severe and mild outcome	119
COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study	78
Long-acting drugs and formulations for the treatment and prevention of HIV infection	71
Emerging Co-Pathogens: New Delhi Metallo-beta-lactamase producing Enterobacterales Infections in New York City COVID-19 Patients	68
Therapeutic plasma exchange in patients with life-threatening COVID-19: a randomised controlled clinical trial	64
Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections	61
Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli	60
Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections	57
HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance	55
Methylene blue inhibits replication of SARS-CoV-2 in vitro	54
Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine	53
Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infecti	52
Octenidine: Novel insights into the detailed killing mechanism of Gram-negative bacteria at a cellular and molecular level	47
High prevalence of colistin resistance and mcr-9/10 genes in Enterobacter spp. in a tertiary hospital over a decade	46
Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: an open-label, non-randomised and controlled trial	45
A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin	40
Klebsiella pneumoniae infections in COVID-19 patients: a 2-month retrospective analysis in an Italian hospital	38
Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals	38
Dysbiosis of the rat vagina is efficiently rescued by vaginal microbiota transplantation or probiotic combination	38
High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial	37
Effect of antibiotics on the human microbiome: a systematic review	36
A pharmacist-led prospective antibiotic stewardship intervention improves compliance to community-acquired pneumonia guidelines in 39 public and private hospitals across South Africa	36
An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis	36

Repositioning of non-antibiotic drugs as an alternative to microbial resistance: a systematic review	35
Artemisinin elevates ergosterol levels of Candida albicans to synergise with amphotericin B against oral candidiasis	34
The current state of laboratory mycology in Asia/Pacific: A survey from the European Confederation of Medical Mycology (ECMM) and International Society for Human and Animal Mycology (ISHAM)	34
Epidemiology and prevalence of extended-spectrum β-lactamase- and carbapenemase-producing Enterobacteriaceae in humans, animals and the environment in West and Central Africa	33
Colistin: from the shadows to a One Health approach for addressing antimicrobial resistance	33
Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections	33
Multidrug-resistant high-risk Enterococcus faecium clones: can we really define them?	33
Candida albicans biofilms: antifungal resistance, immune evasion, and emerging therapeutic strategies	32
Bacteriophage–antibiotic combinations against ciprofloxacin/ceftriaxone-resistant Escherichia coli in vitro and in an experimental Galleria mellonella model	32
Antimicrobial stewardship in the ICU in COVID-19 times: the known unknowns	32